New in vivo cell therapy aims to reprogram immune cells to treat autoimmune disease ImmunoVec will use a $40.7 million grant to advance its polymeric nanoparticle platform toward a first-in-human trial for autoimmune diseases.

https://www.drugdiscoverynews.com/new-in-vivo-cell-therapy-aims-to-reprogram-immune-cells-to-treat-autoimmune-disease-16749